
CLAIMS

1. Use of an IL-8 inhibitor in the manufacture of a medicament for the prevention and/or treatment of chemotherapy-induced neuropathy.
2. The use according to claim 1, wherein the medicament is for the prevention and/or treatment of chemotherapy-induced peripheral neuropathy or chemotherapy-induced optic neuropathy.
3. The use according to claim 2, wherein the medicament is for the prevention and/or treatment of allodynia associated to chemotherapy-induced peripheral neuropathy.
4. The use according to any of the previous claims, wherein the IL-8 inhibitor is selected from small molecular weight molecules and antibodies.
5. The use according to any of the previous claims, wherein the IL-8 inhibitor is an inhibitor of the activity of IL-8 mediated by the CXCR1 receptor.
6. The use according to any of the previous claims, wherein the IL-8 inhibitor is an inhibitor of the activity of IL-8 mediated by both the CXCR1 and CXCR2 receptor.
7. The use according to any one of the previous claims, wherein said 1,3-thiazol-2-ylaminophenylpropionic acid derivatives are compounds of formula (I)



(I)

wherein

-R1 is hydrogen or CH_3;

-R2 is hydrogen or linear C_1-C_4 alkyl, preferably it is hydrogen;

-Y is S;

-Z is selected from halogen, linear or branched C_1-C_4 alkyl, C_2-C_4 alkenyl, C_2-C_4 alkynyl, C_1-C_4 alkoxy, hydroxyl, carboxyl, C_1-C_4 acyloxy, phenoxy, cyano, nitro, amino, C_1-C_4 acylamino, halo C_1-C_3 alkyl, halo C_1-C_3 alkoxy, benzoyl, linear or branched C_1-C_8 alkanesulfonate, linear or branched C_1-C_8 alkanesulfonamide, linear or branched C_1-C_8 alkylsulfonylmethyl; preferably it is trifluoromethyl;

-X is OH, NHR_3, or SO_2R4; wherein R_3 is selected from hydrogen, hydroxyl, linear or branched C_1-C_6 alkyl, C_3-C_6 cycloalkyl, C_2-C_6 alkenyl, C_1-C_5 alkoxy, or C_1-C_6 phenylalkyl, wherein alkyl, cycloalkyl or alkenyl group can be substituted by a COOH and R4 is C_1-C_2 alkyl, C_3-C_6 cycloalkyl, C_1-C_3 haloalkyl.

8. The use according to claim 7, wherein: R1 is hydrogen or CH_3;

X is OH;

R2 is hydrogen or linear C_1-C_4 alkyl,

Y is a heteroatom selected from S, O and N;


Z is selected from linear or branched C_1-C_4 alkyl, linear or branched C_1-C_4 alkoxy, halo C_1-C_3 alkyl and halo C_1-C_3 alkoxy.

9. The use as claimed in claim 7, wherein R1 is hydrogen, the chiral carbon atom of the phenylproprionic group is in the S configuration.

10. The use as claimed in any one of claims 1 to 7, wherein the IL-8 inhibitor is selected from 2-methyl-2-(4-{[4-(trifluoromethyl)-1,3-thiazol-2-yl]amino} phenyl) propanoic acid and pharmaceutically acceptable salts thereof, preferably its sodium salt.

11. The use as claimed in any one of the previous claims, wherein the IL-8 inhibitor is (2S)-2-(4-{[4-(trifluoromethyl)-1,3-thiazol-2-yl] amino} phenyl) propanoic acid and pharmaceutically acceptable salts thereof, preferably its sodium salt.

12. The use as claimed in any one of the previous claims, wherein said 2-phenyl-propionic acid derivatives are compounds of formula (II)



(II)

or a pharmaceutically acceptable salt thereof,


wherein:

R^4 is linear or branched C_1-C_6 alkyl, benzoyl, phenoxy, trifluoromethanesulfonyloxy; preferably it is selected from 3-benzoyl, 4-isobutyl or 4- trifluoromethanesulfonyloxy:

R^5 is H or linear or branched C_1-C_3 alkyl, preferably it is H;

R^6 is linear or branched C_1-C_6 alkyl or trifluoromethyl; preferably, it is a linear or branched C_1-C_6 alkyl, more preferably it is CH_3.

13. The use as claimed in any one of the previous claims, wherein said 2-phenyl-propionic acid derivatives are compounds of formula (III)



(III)

or a pharmaceutically acceptable salts thereof,

wherein

R' is hydrogen;

R is SO_2Ra wherein Ra is linear or branched C_1-C_4 alkyl or halo C_1-C_3 alkyl, preferably it is CH_3.

14. The use as claimed in claim 12 or claim 13, wherein the chiral carbon atom of the phenylpropionic group is in the R configuration.
15. The use as claimed in claim 12 or claim 14, wherein the IL-8 inhibitor is selected from R-(-)-2-(4-isobutylphenyl)propionyl methanesulfonamide and pharmaceutically acceptable salts thereof, preferably the lysine *in situ* salt.
16. The use as claimed in any one of claims 12 to 14, wherein the IL-8 inhibitor is R(-)-2-(4-trifluoromethanesulfonyloxy)phenyl]-N-methanesulfonyl propionamide and pharmaceutically acceptable salts thereof, preferably its sodium salt.
17. The use as claimed in any of the previous claims, wherein the medicament is for the prevention and/or treatment of chemotherapy-induced peripheral neuropathy induced by a chemoterapeutic agent selected from platinum based drugs, taxanes, epothilones, plant alkaloids, thalidomide, lenalidomide and pomalidomide, carfilzomib, bortezomib and eribulin.
18. The use as claimed in claim 17, wherein said chemoterapeutic agent is selected from cisplatin, carboplatin, oxaliplatin, paclitaxel, cabazitaxel, docetaxel, ixabepilone, vinblastine, vincristine, vinorelbine, etoposide, thalidomide, lenalidomide, pomalidomide, carfilzomib, bortezomib and eribulin.
19. The use as claimed in claim 17, wherein said chemotherapeutic agent is selected from taxanes and platinum based drugs.
20. The use as claimed in claim 19, wherein the taxane is Paclitaxel and the platinum based drug is oxaliplatin.